177Lu FAPi RLT / Ratio Therap - LARVOL DELTA

Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure (PRNewswire) - "Proceeds from the financing will fuel Ratio's next phase of growth. The company expects to use the funding to advance its ongoing ATLAS study evaluating its lead radiotherapeutic asset [Ac-225]RTX-2358 in advanced sarcomas, and to move its next-generation RLT candidate into the clinic."

Financing • Non Small Cell Lung Cancer • Sarcoma

Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Checkpoint inhibition • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • FAP